Interferon-α,Interleukin-2,Lymphokine-Activated Killer Cellsを用いた併用免疫療法 進行性腎細胞癌患者のquality of lifeの改善効果の検討
Combined Immunotherapy using Interferon-α, Interleukin-2 and Lymphokine-Activated Killer Cells: Improvement of Quality of Life in Patients with Advanced Renal Cell Carcinoma.
BRUNDA, M. J. In vivo antitumor activity of combination of interferon-α and interleukin-2 in a murine model. Correlation of efficacy with the induction cytotoxic cells resembling natural killer cells. Int. J. Cancer. 1987, 40, 365
ROSENBERG, S. A. Special report: Observation on the systemic administration of autologous lymphokineactivated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313, 1485-1492